IDH1/2 inhibitor (Eli Lilly)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIDH1/2 inhibitor (Eli Lilly)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP], mitochondrial inhibitorsIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmicIsocitrate dehydrogenase [NADP], mitochondrial
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A